Novo Nordisk strikes second licensing deal since frosty capital-markets day
Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.
Source：MarketWatch
友情提醒：請廣大讀者理性看待市場資訊，切實提高風險意識。站內所有內容僅系市場資訊或相關方觀點，不構成任何形式投資建議。